Treatment characteristics and safety profiles of Belbuca®, buprenorphine patch, and oral schedule II opioids among chronic low back pain patients without a positive history of opioid-use disorder: a retrospective US commercial claims analysis - Top-Institutions - MDSpire

Treatment characteristics and safety profiles of Belbuca®, buprenorphine patch, and oral schedule II opioids among chronic low back pain patients without a positive history of opioid-use disorder: a retrospective US commercial claims analysis

  • By

  • Vladimir Zah

  • Dimitrije Grbic

  • Filip Stanicic

  • June 30, 2026

  • 0 min

Share

Top Institutions in Family Medicine

Brief introduction explaining scope and methodology.

  • #1

    Brigham and Women’s Hospital
    Brigham and Women’s Hospital

    Boston, Massachusetts

    Key Differentiators

    • Pain Medicine
    • Pharmacoepidemiology

  • #2

    Stanford Health Care
    Stanford Health Care

    Stanford, California

    Key Differentiators

    • Pain Medicine
    • Pharmacoepidemiology

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Pain Medicine
    • Chronic Pain Management

  • #4

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, Ohio

    Key Differentiators

    • Pain Medicine
    • Pain Management

  • #5

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, Maryland

    Key Differentiators

    • Pain Medicine
    • Pain Management

Original Source(s)

Treatment characteristics and safety profiles of Belbuca®, buprenorphine patch, and oral schedule II opioids among chronic low back pain patients without a positive history of opioid-use disorder: a retrospective US commercial claims analysis

  • by Vladimir Zah, Dimitrije Grbic, Filip Stanicic

  • June 30, 2026

Related Content

Leveraging Learning Health Systems to Address Racial and Ethnic Disparities in Veteran Patient Experience

Stair use and risk of incident rheumatic and non-rheumatic valvular heart disease: a cohort study from the UK biobank

Surveillance May Reduce CIN 2 Overtreatment

Risk-based management may reduce unnecessary excisions in selected patients with CIN 2.